Article
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
The Journal of infectious diseases - 13 Dec 2022
Eshleman Susan H, Fogel Jessica M, Halvas Elias K, Piwowar-Manning Estelle, Marzinke Mark A, Kofron Ryan, Wang Zhe, Mellors John, McCauley Marybeth, Rinehart Alex R, St Clair Marty, Adeyeye Adeola, Hinojosa Juan C, Cabello Robinson, Middelkoop Keren, Hanscom Brett, Cohen Myron S, Grinsztejn Beatriz, Landovitz Raphael J
Abstract excerpt
BACKGROUND: The HPTN 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was superior to tenofovir-disoproxil fumarate/emtricitabine for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP). Integrase strand transfer inhibitor (INSTI) resistance-associated mutations (RAMs) were detected in some participants with HIV infection. We used a low viral load INSTI genotyping assay to evaluate the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.